SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Endocrinology Consultation — Alan Turing — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Alan Turing |
|---|
| Date of birth | 1912-06-23 |
|---|
| Identifiers | MRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290 |
|---|
| Document date | 1953-04-28 |
|---|
| Author | Celia Montrose-Adeyemi, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Bilateral tender gynecomastia, suppressed testosterone and gonadotropins, and low libido in a 40-year-old man three weeks after the last of a year of high-dose estrogen injections given without his free consent. Please confirm the cause, advise what further tests are needed, and advise on recovery, testosterone therapy, bone health, and surgery. [S]
Urgency: Soon, within two weeks. [S]
Questions for the consultant:
- Does the exogenous estrogen fully explain the gynecomastia and the hormone results, and what further tests are needed to exclude another cause?
- How quickly should the hypothalamic-pituitary-gonadal axis recover, and how should we monitor it?
- Is testosterone therapy, tamoxifen, or an aromatase inhibitor indicated now?
- Is the raised prolactin significant?
- How should we protect and assess his bone health?
- When should surgery be considered if the gynecomastia persists?
History of Present Illness
Mr. Turing is seen at the request of Dr. Hallam, five weeks after the last of about a year of high-dose estrogen injections that were imposed on him abroad as the alternative to imprisonment. He did not consent freely and will not take them again. Breast enlargement began within a few months of the injections and became tender; libido and erections were lost over the same months. He has no testicular pain or swelling, nipple discharge, headache, visual disturbance, or galactorrhea. He has never used anabolic steroids, androgens, or other drugs linked to gynecomastia and has no liver, kidney, or thyroid disease. He has had no leg swelling, chest pain, or breathlessness. He runs 20 to 40 km a week. His sexual orientation was discussed only as he chose; it has no bearing on these findings. He asked for each step of the examination to be explained, and agreed to each. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Alan Mathison Turing was born on 23 June 1912 in a nursing home in Paddington, London. [D]
- He was a long-distance runner: he built his strength in cross-country running, was known for running to scientific meetings, and in 1951 was still training for long-distance running on the roads around Wilmslow, where he had bought his first house. [D]
- After reporting a burglary at his home in 1952 he was arrested over a relationship with another man and tried on 31 March 1952 for "gross indecency"; rather than go to prison he accepted, for a year, oestrogen treatment intended to neutralise his libido. [D]
- His biographer Andrew Hodges writes that the drug was probably stilboestrol, a synthetic oestrogen; the 2009 government statement and other sources describe the treatment as a series of injections of female hormones. [D]
- Hodges describes the injurious and humiliating effect of the hormones on his body; it is often repeated that the treatment made him grow breasts, though he is known to have mentioned this only once. [D]
- In a letter of 23 November 1952 he wrote that he had decided to have "another, and rather more co-operative go at a psychiatrist"; this was Jungian analysis with a refugee analyst, and he became very enthusiastic about it and wrote down all his dreams. [D]
- His conviction led to the removal of his security clearance, so that he could no longer work for Government Communications Headquarters as he had since the war. [D]
- After the trial he returned to a wide range of academic work, including morphogenesis, quantum theory, and relativity, at Manchester University. [D]
- The roster lists depression as a primary condition; the sources read document his prosecution, the hormone treatment, and his decision to seek Jungian analysis, but record no diagnosis of depression, so a depressive illness is a retrospective interpretation. [R]
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1953-04-14 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed |
N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | active | confirmed |
E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed |
T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed |
F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed |
E55.9 | S — Synthetic finding of the bone-health workup. |
Physical Exam
Vital signs recorded on 1953-04-28; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Tall, lean man; normal male hair distribution |
| Breast | Examined with his agreement: firm, tender, rubbery, symmetric glandular tissue about 4 cm across behind each nipple; no discrete or eccentric mass, skin change, nipple discharge, or axillary nodes |
| Genitourinary | Examined with his agreement: testes soft and slightly small without masses, as the ultrasound confirms |
| Neck | No thyroid enlargement |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1953-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | | | S |
| 1953-04-28 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 46 | pg/mL | 7.6-42.6 pg/mL | High | S |
| 1953-04-28 | Lutropin [Units/volume] in Serum or Plasma | 0.9 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Low | S |
Assessment
- Bilateral gynecomastia (N62). True gynecomastia, typical on examination and fully explained by a year of high-dose exogenous estrogen. hCG and AFP are normal and the scrotal ultrasound shows no mass, so a testicular tumor is excluded; liver, kidney, and thyroid disease are excluded. Breast imaging is not needed because the examination is typical and shows no discrete mass. Most gynecomastia of recent onset regresses once the cause is removed, though tissue present for many months may become fibrous and persist. [S]
- Drug-induced hypogonadotropic hypogonadism (E23.1). Suppression of LH, FSH, and testosterone by exogenous estrogen, with estradiol already falling. Recovery is expected over two to six months. Testosterone therapy would suppress the axis again and is not indicated for a transient, drug-induced deficiency. Tamoxifen and aromatase inhibitors are not justified in general and are not needed here. The mildly raised prolactin is an expected estrogen effect and should be rechecked after the estrogen clears; no pituitary imaging is needed unless it stays raised. [S]
- Adverse effects of high-dose estrogen given without free consent (T38.5X5A). An iatrogenic harm. He has no symptoms or signs of venous thrombosis, and his liver tests are normal. The treatment had no medical indication. [S]
- Vitamin D insufficiency (E55.9). Appropriate to replace while testosterone is low. [S]
Data reviewed: The intake results, today's estradiol of 46 pg/mL and LH of 0.9 mIU/mL, and today's scrotal ultrasound, which shows testes of about 15 mL each, homogeneous, with no mass and no varicocele. [S]
Plan of Treatment
- No further estrogen; watchful waiting for the gynecomastia. [S]
- No testosterone therapy, tamoxifen, or aromatase inhibitor while the axis recovers. [S]
- Testosterone, estradiol, LH, FSH, prolactin, and hemoglobin about six weeks from now, then every six to eight weeks until normal; testosterone and estradiol once more at about six months. [S]
- Continue cholecalciferol 1,000 units daily, calcium from food, and running with strength work; a bone density scan only if hypogonadism persists beyond six months or a fragility fracture occurs. [S]
- Breast imaging only if the examination becomes equivocal or a discrete mass appears. [S]
- A plastic surgery opinion if the gynecomastia persists about twelve months after the estrogen stopped and he wants it removed. [S]
- Return to endocrinology if testosterone remains low or LH and FSH have not recovered six months after the last dose, or if prolactin stays raised. [S]
- Discussed with Dr. Hallam the same day; Mr. Turing agrees with the plan and has a written copy. [S]
- Follow-up: Primary care monitors recovery. Endocrinology is available for review on the criteria above. [S]